Program
zosurabalpin
Its studies are mostly in Bacterial Infections, led by Hoffmann-La Roche.
Furthest: phase 1, since Oct 23, 20202 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 20 open or running | phase 1since Oct 23, 2020 | Oct 23, 2020 | none ahead |
- Named in Hoffmann-La Roche’s own pipeline as
RG6006 zosurabalpin
, phase 1, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 23, 2020First study: phase 1 study in Healthy VolunteersFirst studyNCT04605718 · 124 enrolled · United States
- Nov 10, 2022Phase 1 study in Bacterial InfectionsNCT05614895 · 48 enrolled · United States, France, Israel and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05614895Bacterial Infections · United States, France, Israel and more | 1 | Completed | Jan 13, 2024 | 48 |
| NCT04605718Healthy Volunteers · United States | 1 | Completed | Mar 9, 2023 | 124 |
How it is read
Names in the registry
- “RO7223280”, 3 entries
Conditions, from the studies’ own filings
- Bacterial Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.